Clinical RCT on the improvement of cardiopulmonary function in patients with novel coronavirus infection during the recovery period by comprehensive sequential therapy of Chinese medicine

ABSTRACT

Conditionlong-covid syndrome

Interventiontreatment groupChinese Herbal Medicine and Snap-Needle Therapy;control groupWestern medicine for symptomatic treatment;

Primary outcome:Chinese Medicine Score;

CriteriaInclusion criteria ?Patients who meet the above diagnostic criteria of traditional Chinese medicine and western medicine;
? Age 18-65 years old, gender is not limited;
? Patients more than 1 week after negative nucleic acid or antigen test;
? Patients with symptoms of impaired cardiopulmonary function, such as cough, fatigue, palpitation, etc., which last for no more than half a year after turning negative from nucleic acid or antigen test;
? Patient's TCM evidence points, according to the symptoms in the recovery period, the primary symptoms are evaluated according to 0, 1, 2, 3 points, and the secondary symptoms are evaluated according to the presence or absence of the symptoms, using 1 or 0 points, and the sum of the scores is recorded as the TCM evidence points, and the higher the score, the more serious the condition is.
? Patients volunteered to be tested and signed an informed consent form.

Exclusion criteria ?Patients with severe interstitial lung disease, bronchiectasis, and other underlying lung diseases;
? Patients with underlying diseases such as congenital respiratory malformations and congenital heart disease;
? Patients with severe cardiac, hepatic, renal dysfunction and abnormal coagulation function;
?Patients with diseases that affect cognitive function, such as alcoholism, drug addiction or psychotropic substance abuse;
? People with history of needle fainting and skin infection at the site of needling;
? Patients who are allergic to Chinese medicinal preparations;
? Pregnant or lactating women;
? Those who are participating in other clinical trials or those who have participated in other clinical trials for less than 3 months. Those who meet any of the above criteria should be excluded.